c-FLIP Mediates Resistance of Hodgkin/Reed-Sternberg Cells to Death Receptor-induced Apoptosis

Journal of Experimental Medicine

Volumn 199, Issue 8, 2004, Pages 1041-1052

  Mathas, Stephan ^a,b   Lietz, Andreas ^b   Anagnostopoulos, Ioannis ^c   Hummel, Franziska ^b   Wiesner, Burkhard ^d   Janz, Martin ^b   Jundt, Franziska ^b   Hirsch, Burkhard ^c   Jöhrens Leder, Korinna ^c   Vornlocher, Hans Peter ^e   Bommert, Kurt ^b   Stein, Harald ^c   Dörken, Bernd ^a,b  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

^e Ribopharma AG   (Germany)

Author keywords

CD95 antigen; Lymphoma; NF B; siRNA; TRAIL protein

Indexed keywords

CASPASE 10; CASPASE 8; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OLIGORIBONUCLEOTIDE; PROTEIN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; UPREGULATION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIGENS, CD95; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BASE SEQUENCE; CARRIER PROTEINS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 10; CASPASE 8; CASPASES; CELL LINE, TUMOR; CYCLOHEXIMIDE; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; HODGKIN DISEASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE GLYCOPROTEINS; NF-KAPPA B; REED-STERNBERG CELLS; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2442545178     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20031080     Document Type: Article

References (63)

1. Locksley, R.M., N. Killeen, and M.J. Lenardo. 2001. The TNF and TNF receptor superfamilies: integrating manimalian biology. Cell. 104:487-501.
2. Peter, M.E., and P.H. Krammer. 2003. The CD95(APO-1/ Fas) DISC and beyond. Cell Death Differ. 10:26-35.
3. Smyth, M.J., K. Takeda, Y. Hayakawa, J.J. Peschon, M.R. van den Brink, and H. Yagita. 2003. Nature's TRAIL-on a path to cancer immunotherapy. Immunity. 18:1-6.
4. Irmler, M., M. Thome, M. Hahne, P. Schneider, K. Hofmann, V. Steiner, J.L. Bodmer, M. Schroter, K. Bums, C. Mattmann, et al. 1997. Inhibition of death receptor signals by cellular FLIP. Nature. 388:190-195.
5. Thome, M., and J. Tschopp. 2001. Regulation of lymphocyte proliferation and death by FLIP. Nat. Rev. Immunol. 1:50-58.
6. Krueger, A., S. Baumann, P.H. Krammer, and S. Kirchhoff. 2001. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol. Cell. Biol. 21:8247-8254.
7. Takahashi, Y., H. Ohta, and T. Takemori. 2001. Fas is required for clonal selection in germinal centers and the subsequent establishment of the memory B cell repertoire. Immunity. 14:181-192.
8. Siegel, R.M., F.K. Chan, H.J. Chun, and M.J. Lenardo. 2000. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat. Immunol. 1:469-474.
9. Defrance, T., M. Casamayor-Palleja, and P.H. Krammer. 2002. The life and death of a B cell. Adv. Cancer Res. 86:195-225.
10. Krammer, P.H. 1999. CD95(APO-1/Fas)-mediated apoptosis: live and let die. Adv. Immunol. 71:163-210.
11. Adachi, M., S. Suematsu, T. Kondo, J. Ogasawara, T. Tanaka, N. Yoshida, and S. Nagata. 1995. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat. Genet. 11:294-300.
12. Davidson, W.F., T. Giese, and T.N. Fredrickson. 1998. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J. Exp. Med. 187: 1825-1838.
13. Hennino, A., M. Berard, P.H. Krammer, and T. Defrance. 2001. FLICE-inhibitory protein is a key regulator of germinal center B cell apoptosis. J. Exp. Med. 193:447-458.
14. Fleisher, T.A., J.M. Puck, W. Strober, J.K. Dale, M.J. Lenardo, R.M. Siegel, S.E. Straus, and J.J. Bleesing. 2001. The autoimmune lymphoproliferative syndrome. A disorder of human lymphocyte apoptosis. Clin. Rev. Allergy Immunol. 20: 109-120.
15. Straus, S.E., E.S. Jaffe, J.M. Puck, J.K. Dale, K.B. Elkon, A. Rosen-Wolff, A.M. Peters, M.C. Sneller, C.W. Hallahan, J. Wang, et al. 2001. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood. 98:194-200.
16. Müschen, M., K. Rajewsky, M. Kronke, and R. Küppers. 2002. The origin of CD95-gene mutations in B-cell lymphoma. Trends Immunol. 23:75-80.
17. Küppers, R., I. Schwering, A. Bräuninger, K. Rajewsky, and M.L. Hansmann. 2002. Biology of Hodgkin's lymphoma. Ann. Oncol. 13:11-18.
18. Karin, M., and Y. Ben-Neriah. 2000. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 18:621-663.
19. Karin, M., Z. Liu, and E. Zandi. 1997. AP-1 function and regulation. Curr. Opin. Cell Biol. 9:240-246.
20. Bargou, R.C., F. Emmerich, D. Krappmann, K. Bommert, M.Y. Mapara, W. Arnold, H.D. Royer, E. Grinstein, A. Greiner, C. Scheidereit, et al. 1997. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J. Clin. Invest. 100: 2961-2969.
21. Mathas, S., M. Hinz, I. Anagnostopoulos, D. Krappmann, A. Lietz, F. Jundt, K. Bommert, F. Mechta-Grigoriou, H. Stein, B. Dörken, et al. 2002. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J. 21:4104-4113.
22. Hinz, M., P. Lernke, I. Anagnostopoulos, C. Hacker, D. Krappmann, S. Mathas, B. Dörken, M. Zenke, H. Stein, and C. Scheidereit. 2002. Nuclear factor κB-dependent gene expression profiling of Hodgldn's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J. Exp. Med. 196:605-617.
23. Hinz, M., P. Löser, S. Mathas, D. Krappmann, B. Dörken, and C. Scheidereit. 2001. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/ Reed-Sternberg cells. Blood. 97:2798-2807.
24. Barth, T.F., J.I. Martin-Subero, S. Joos, C.K. Menz, C. Hasel, G. Mechtersheimer, R.M. Parwaresch, P. Lichter, R. Siebert, and P. Möller. 2003. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood. 101: 3681-3686.
25. Schwering, I., A. Bräuninger, U. Klein, B. Jungnickel, M. Tinguely, V. Diehl, M.L. Hansmann, R. Dalla-Favera, K. Rajewsky, and R. Küppers. 2003. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 101:1505-1512.
26. Schroter, M., J. Peli, M. Hahne, J. Tschopp, and E. Reichmann. 2000. Fas-dependent tissue turnover is implicated in tumor cell clearance. Oncogene. 19:1794-1800.
27. Medema, J.P., J. de Jong, T. van Hall, C.J. Melief, and R. Offringa. 1999. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 190: 1033-1038.
28. French, L.E., and J. Tschopp. 2002. Defective death receptor signaling as a cause of tumor immune escape. Semin. Cancer Biol. 12:51-55.
29. Maggio, E.M., A. Van Den Berg, D. de Jong, A. Diepstra, and S. Poppema. 2003. Low frequency of FAS mutations in Reed-Sternberg cells of Hodgkin's lymphoma. Am. J. Pathol. 162:29-35.
30. Re, D., A. Hofmann, J. Wolf, V. Diehl, and A. Staratschekjox. 2000. Cultivated H-RS cells are resistant to CD95L-mediated apoptosis despite expression of wild-type CD95. Exp. Hematol. 28:348.
31. Thomas, R.K., A. Kallenborn, C. Wickenhauser, J.L. Schultze, A. Draube, M. Vockerodt, D. Re, V. Diehl, and J. Wolf. 2002. Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am. J. Pathol. 160:1521-1528.
32. Xerri, L., F. Palmerini, E. Devilard, T. Defrance, R. Bouabdallah, J. Hassoun, and F. Birg. 2000. Frequent nuclear localization of ICAD and cytoplasmic co-expression of caspase-8 and caspase-3 in human lymphomas. J. Pathol. 192:194-202.
33. Siegmund, D., P. Hadwiger, K. Pfizenmaier, H.P. Vomlocher, and H. Wajant. 2002. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. Mol. Med. 8:725-732.
34. Scaffidi, C., F.C. Kischkel, P.H. Krammer, and M.E. Peter. 2000. Analysis of the CD95 (APO-1/Fas) death-inducing signaling complex by high-resolution two-dimensional gel electrophoresis. Methods Enzymol. 322:363-373.
35. Harris, N.L., E.S. Jaffe, H. Stein, P.M. Banks, J.K. Chan, M.L. Cleary, G. Delsol, C. De Wolf-Peeters, B. Falini, and K.C. Gatter. 1994. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 84:1361-1392.
36. Schmitz, I., A. Krueger, S. Baumann, S. Kirchhoff, and P.H. Krammer. 2002. Specificity of anti-human CD95 (APO-1/ Fas) antibodies. Biochem. Biophys. Res. Commun. 297:459-462.
37. Strater, J., S.M. Mariani, H. Walczak, F.G. Rucker, F. Leithauser, P.H. Krammer, and P. Moller. 1999. CD95 ligand (CD95L) in normal human lymphoid tissues: a subset of plasma cells are prominent producers of CD95L. Am. J. Pathol. 154:193-201.
38. Schmitz, I., H. Walczak, P.H. Krammer, and M.E. Peter. 1999. Differences between CD95 type I and II cells detected with the CD95 ligand. Cell Death Differ. 6:821-822.
39. Kischkel, F.C., D.A. Lawrence, A. Tinel, H. LeBlanc, A. Virmani, P. Schow, A. Gazdar, J. Blenis, D. Amott, and A. Ashkenazi. 2001. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J. Biol. Chem. 276:46639-46646.
40. Xerri, L., N. Carbuccia, P. Parc, J. Hassoun, and F. Birg. 1995. Frequent expression of FAS/APO-1 in Hodgkin's disease and anaplastic large cell lymphomas. Histopathology. 27: 235-241.
41. Metkar, S.S., K.N. Naresh, A.A. Redkar, C.S. Soman, S.H. Advani, and J.J. Nadkarni. 1999. Expression of Fas and Fas ligand in Hodgkin's disease. Leuk. Lymphoma. 33:521-530.
42. Kreuz, S., D. Siegmund, P. Scheurich, and H. Wajant. 2001. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol. Cell. Biol. 21:3964-3973.
43. Chinnaiyan, A.M., K. O'Rourke, M. Tewari, and V.M. Dixit. 1995. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell. 81:505-512.
44. Ohshima, K., S. Haraoka, M. Sugihara, J. Suzumiya, C. Kawasaki, M. Kanda, and M. Kikuchi. 2000. Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas. Cancer Lett. 160: 89-97.
45. French, L.E., and J. Tschopp. 1999. Inhibition of death receptor signaling by FLICE-inhibitory protein as a mechanism for immune escape of tumors. J. Exp. Med. 190:891-894.
46. Kataoka, T., R.C. Budd, N. Holler, M. Thome, F. Martinon, M. Irmler, K. Burns, M. Hahne, N. Kennedy, M. Kovacsovics, et al. 2000. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr. Biol. 10:640-648.
47. Djerbi, M., V. Screpanti, A.I. Catrina, B. Bogen, P. Biberfeld, and A. Grandien. 1999. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J. Exp. Med. 190:1025-1032.
48. Ravi, R., G.C. Bedi, L.W. Engstrom, Q. Zeng, B. Mookerjee, C. Gelinas, E.J. Fuchs, and A. Bedi. 2001. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat. Cell Biol. 3:409-416.
49. Zong, W.X., J. Bash, and C. Gelinas. 1998. Rel blocks both anti-Fas- and TNF alpha-induced apoptosis and an intact Rel transactivation domain is essential for this effect. Cell Death Differ. 5:963-972.
50. Möller, P., K. Koretz, F. Leithauser, S. Bruderlein, C. Henne, A. Quentmeier, and P.H. Krammer. 1994. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer. 57:371-377.
51. Robertson, M.J., T.J. Manley, G. Pichert, C. Cameron, K.J. Cochran, H. Levine, and J. Ritz. 1995. Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk. Lymphoma. 17:51-61.
52. Strand, S., W.J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S.M. Mariani, W. Stremmel, P.H. Krammer, and P.R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat. Med. 2:1361-1366.
53. Sakuma, I., T. Yoshino, K. Omonishi, R. Nishiuchi, N. Teramoto, H. Yanai, K. Kawahara, I. Kubonishi, Y. Matsuo, and T. Akagi. 1999. CD95 ligand is expressed in Reed-Sternberg cells of Hodgkin's disease. Pathol. Int. 49:103-109.
54. Wajant, H., K. Pfizenmaier, and P. Scheurich. 2003. Non-apoptotic Fas signaling. Cytokine Growth Factor Rev. 14:53-66.
55. Desbarats, J., R.B. Birge, M. Mimouni-Rongy, D.E. Weinstein, J.S. Palerme, and M.K. Newell. 2003. Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat. Cell Biol. 5:118-125.
56. Rescigno, M., V. Piguet, B. Valzasina, S. Lens, R. Zubler, L. French, V. Kindler, J. Tschopp, and P. Ricciardi-Castagnoli. 2000. Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1β, and the production of interferon γ in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory responses. J. Exp. Med. 192:1661-1668.
57. Ponton, A., M.V. Clement, and I. Stamenkovic. 1996. The CD95 (APO-1/Fas) receptor activates NF-kappaB independently of its cytotoxic function. J. Biol. Chem. 271:8991-8995.
58. Schaub, F.J., D.K. Han, W.C. Liles, L.D. Adams, S.A. Coats, R.K. Ramachandran, R.A. Seifert, S.M. Schwartz, and D.F. Bowen-Pope. 2000. Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nat. Med. 6:790-796.
59. Choi, C., G.Y. Gillespie, N.J. Van Wagoner, and E.N. Benveniste. 2002. Fas engagement increases expression of interleukin-6 in human glioma cells. J. Neurooncol. 56:13-19.
60. Stohl, W., D. Xu, G.C. Starling, P. Casali, and P.A. Kiener. 2000. Promotion of activated human B cell apoptosis and inhibition of Ig production by soluble CD95 ligand: CD95-based downregulation of Ig production need not culminate in activated B cell death. Cell. Immunol. 203:1-11.
61. Carbone, A., A. Gloghini, V. Gattei, D. Aldinucci, M. Degan, P. De Paoli, V. Zagonel, and A. Pinto. 1995. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood. 85:780-789.
62. Dürkop, H., U. Latza, M. Hummel, F. Eitelbach, B. Seed, and H. Stein. 1992. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 68:421-427.
63. Fiumara, P., V. Snell, Y. Li, A. Mukhopadhyay, M. Younes, A.M. Gillenwater, F. Cabanillas, B.B. Aggarwal, and A. Younes. 2001. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood. 98: 2784-2790.